What Are the Effects of Psilocybin Therapy for Depression?
Overview Integrating science and spirituality is like mixing oil and water since these two subjects are generally thought to be on two immiscible, polar-opposite ends of a spectrum. Nonetheless, a growing number of scientists in the biohacking community are looking into a mysterious substance rooted deeply in the indigenous culture and has been used for spiritual, medicinal, and religious purposes for thousands of years – psilocybin. This article aims to review the latest findings on psilocybin, how it is effective as a treatment option for depression, and whether it will be available as a standard pharmaceutical in conjunction with traditional therapies in psychiatry. RELATED: The Rise of Psychedelic Medicine | What We Know So Far What is Psilocybin Therapy? Understanding Psilocybin and Psilocybin Mushroom Psilocybin is a psychoactive and hallucinogenic compound derived from certain types of mushrooms, known as psilocybin mushrooms or often colloquially referred to as “magic mushrooms” or “shrooms.” Psilocybin mushrooms are a group of fungi that contain psilocybin. Some examples of psilocybin mushrooms include: Psilocybe cubensis (Stropharia cubensis) Psilocybe caerulescens (Landslide Mushroom) Psilocybe mexicana (Teonanacatl or Pajaritos) Psilocybe caerulipes (Blue Foot Mushroom) Psilocybe stuntzii (Blue Ringer Mushroom) The History of Psilocybin Therapy Researchers first began studying psilocybin in the 1950s, particularly when chemist Albert Hofmann isolated psilocybin and identified it as the active compound in psychoactive mushrooms in 1958. Even then, psilocybin was a promising therapeutic drug for several mental health conditions. However, psilocybin was banned during the 1970s, resulting in tremendous difficulties among scientists continuing research on the substance. Psilocybin was then classified as a Schedule I substance, meaning the compound had a high potential for abuse and was forbidden from medical and clinical use. It was not until several decades later that Dr. Roland Griffiths from Johns Hopkins University restarted psilocybin research in 1999, allowing the once Schedule I substance to be reclassified and legally studied among healthy volunteers. Psilocybin Therapy in Today’s Psychiatry Since the restart, the progress in psilocybin and psilocybin therapy research has been significant and promising enough to attract a wider group of scientists and potentially become a branch of mainstream science. Today, many psychiatrists, psychologists, and scientists consider psilocybin therapy a promising, near-standard treatment option to complement traditional therapies in treating mental health conditions. So, what exactly is psilocybin therapy? Psilocybin therapy, also known as “shroom therapy,” involves ingestion of psilocybin in a certain way, either through oral consumption, liquid administration, or fume inhalation. Psilocybin use induces psychological effects that are thought to contribute to the treatment of depression and provide a complementary strategy to conventional therapies. RELATED: Psychedelics Research and Psilocybin Therapy How Does Psilocybin Therapy Work for Depression? After ingestion, psilocybin is rapidly metabolized to psilocin, the primary, active substance that causes psychological effects on the user. Psilocybin is therefore considered a “prodrug” (an inactive substance that can be converted into an active one) to psilocin. According to a study by the MDPI, some possible mechanisms of action by which psilocybin produces antidepressant effects include: Psilocybin Deactivates or Normalizes the Hyperactivity of the Brain The medial prefrontal cortex frequently exhibits hyperactivity during depressive disorders. Psilocybin may work as an antidepressant by deactivating or normalizing the medial prefrontal cortex’s typical level of hyperactivity. Psilocybin Modulates the Brain Regions Responsible for Emotion-processing Psilocybin’s antidepressant effects are mediated by its ability to modulate certain brain areas, particularly the amygdala. The amygdala, located deep within the brain’s temporal lobes, is responsible for sensory and emotional responses. Psilocybin Interacts With or Alters the Default-mode Network (DMN) Another way psilocybin might exert its antidepressant properties is through interaction with or alteration of the default-mode network (DMN). For example, some of the regions of the brain involved in emotional thinking may negatively affect the DMN in depression, causing resting cognition to be taken over by negative feelings. Psilocybin Increases Dopamine, a Neurotransmitter Responsible for Emotion Regulation The last possible mechanism may be the ability of psilocybin to increase dopamine, a neurotransmitter in charge of controlling emotions and even a person’s physical well-being. RELATED: 4 Genius Ways to Biohacking Your Brain Evidence for Psilocybin Therapy as the Treatment of Depression Research by the Journal of Psychopharmacology According to a study on the effects of psilocybin on depression and anxiety in 51 cancer patients, high doses of the drug resulted in significant, positive changes in both clinician- and patient-rated indicators. These changes include reduced depressed mood and anxiety and the fear of death, as well as increases in optimism, quality of life, and life meaning. At the 6-month follow-up, these changes had persisted, with over 80% of subjects still displaying significant improvement in anxiety and depressive mood. Research by Springer Psychopharmacology The efficacy of psilocybin therapy for depression is backed by another study, in which 20 patients with severe treatment-resistant depression were assigned to two oral doses of psilocybin. The study found that psilocybin treatment improved depression after six months, with no patients seeking conventional antidepressant treatment within five weeks of psilocybin. The study also implies that psilocybin may protect against depression to a comparable extent to the daily use of antidepressants. Research by JAMA Psychiatry One of the most recent studies published in 2020 has also found that psilocybin-assisted therapy is effective among patients with major depressive disorder. Specifically, findings suggest that psilocybin can help treat the condition in 24 participants after two sessions. Is Psilocybin Therapy Safe, Addictive, or Legal? Psilocybin Therapy Safety Psilocybin therapy is still in the infancy of experimental research, and the data collected from all the relevant trials remain insufficient to conclude if it is entirely safe. Still, research by The Lancet Medical Journal shows that mushrooms are surprisingly much less harmful than other recreational drugs and substances, like alcohol or tobacco. However, the statistics above do not mean that psilocybin is risk-free. Initial trials on the substance have shown that users may experience some physical and mental side effects in case of abuse. As